Search

Search Constraints

You searched for: Author/Creator Dusetti, Nelson

Search Results

1. Back Cover: Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer (EXP2 1/2021). Issue 1 (1st September 2021)

2. Basal‐like and classical cells coexist in pancreatic cancer revealed by single‐cell analysis on biopsy‐derived pancreatic cancer organoids from the classical subtype. Issue 9 (20th July 2020)

3. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). (2nd January 2018)

4. Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. Issue 1 (27th August 2021)

5. Discovery and 3D imaging of a novel ΔNp63-expressing basal cell type in human pancreatic ducts with implications in disease. Issue 10 (30th July 2021)

6. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Issue 9 (20th June 2016)

7. Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. Issue 4 (8th March 2017)

8. Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. Issue 6 (11th September 2013)

9. Ketogenic HMG‐CoA lyase and its product β‐hydroxybutyrate promote pancreatic cancer progression. (21st March 2022)